181 related articles for article (PubMed ID: 25815142)
1. Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.
Johannes JW; Almeida L; Barlaam B; Boriack-Sjodin PA; Casella R; Croft RA; Dishington AP; Gingipalli L; Gu C; Hawkins JL; Holmes JL; Howard T; Huang J; Ioannidis S; Kazmirski S; Lamb ML; McGuire TM; Moore JE; Ogg D; Patel A; Pike KG; Pontz T; Robb GR; Su N; Wang H; Wu X; Zhang HJ; Zhang Y; Zheng X; Wang T
ACS Med Chem Lett; 2015 Mar; 6(3):254-9. PubMed ID: 25815142
[TBL] [Abstract][Full Text] [Related]
2. Evidence for tankyrases as antineoplastic targets in lung cancer.
Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
[TBL] [Abstract][Full Text] [Related]
4. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
5. Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.
Dowling JE; Alimzhanov M; Bao L; Chuaqui C; Denz CR; Jenkins E; Larsen NA; Lyne PD; Pontz T; Ye Q; Holdgate GA; Snow L; O'Connell N; Ferguson AD
ACS Med Chem Lett; 2016 Mar; 7(3):300-5. PubMed ID: 26985319
[TBL] [Abstract][Full Text] [Related]
6. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
7. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
[TBL] [Abstract][Full Text] [Related]
8. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.
Riccio AA; McCauley M; Langelier MF; Pascal JM
Structure; 2016 Sep; 24(9):1573-81. PubMed ID: 27499439
[TBL] [Abstract][Full Text] [Related]
9. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
10. Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.
Koirala S; Klein J; Zheng Y; Glenn NO; Eisemann T; Fon Tacer K; Miller DJ; Kulak O; Lu M; Finkelstein DB; Neale G; Tillman H; Vogel P; Strand DW; Lum L; Brautigam CA; Pascal JM; Clements WK; Potts PR
Cell Rep; 2020 Jul; 32(3):107922. PubMed ID: 32698014
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
[TBL] [Abstract][Full Text] [Related]
12. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
13. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W
J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
15. Tankyrase Inhibitor for Cardiac Tissue Regeneration: an
Hosseini FS; Amanlou A; Amanlou M
Iran J Pharm Res; 2021; 20(4):315-328. PubMed ID: 35194449
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS
Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876
[TBL] [Abstract][Full Text] [Related]
17. The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models.
Brinch SA; Amundsen-Isaksen E; Espada S; Hammarström C; Aizenshtadt A; Olsen PA; Holmen L; Høyem M; Scholz H; Grødeland G; Sowa ST; Galera-Prat A; Lehtiö L; Meerts IATM; Leenders RGG; Wegert A; Krauss S; Waaler J
Cancer Res Commun; 2022 Apr; 2(4):233-245. PubMed ID: 36873622
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
19. Tankyrase is necessary for canonical Wnt signaling during kidney development.
Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
[TBL] [Abstract][Full Text] [Related]
20. Tankyrase: a promising therapeutic target with pleiotropic action.
Sagathia V; Patel C; Beladiya J; Patel S; Sheth D; Shah G
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3363-3374. PubMed ID: 37338576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
